UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Update on afatinib-based combination regimens for the treatment of EGFR mutation-positive non-small-cell lung cancer

Future oncology (London, England), 2017-09, Vol.13 (21), p.1829-1833

Bennouna, Jaafar

2017

Volltextzugriff (PDF)

Two-Year Survival Comparing Web-Based Symptom Monitoring vs Routine Surveillance Following Treatment for Lung Cancer

JAMA : the journal of the American Medical Association, 2019-01, Vol.321 (3), p.306

2019

Volltextzugriff (PDF)

Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer

Journal of clinical oncology, 2020-12, Vol.38 (35), p.4138-4148

2020

Volltextzugriff (PDF)

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations

Journal of clinical oncology, 2013-09, Vol.31 (27), p.3327-3334

2013

Volltextzugriff (PDF)

Treatments for Non-Small-Cell Lung Cancer: The Multiple Options for Precision Medicine

Current oncology (Toronto), 2022-09, Vol.29 (10), p.7106-7108

2022

Volltextzugriff (PDF)

Infiltrating and peripheral immune cell analysis in advanced gastric cancer according to the Lauren classification and its prognostic significance

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2020-01, Vol.23 (1), p.73-81

2020

Volltextzugriff (PDF)

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

The lancet oncology, 2015-02, Vol.16 (2), p.141-151

2015

Volltextzugriff (PDF)

KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer

Future oncology (London, England), 2019-04, Vol.15 (10), p.1057-1066

2019

Volltextzugriff (PDF)

Investigating beam matching for multi-room pencil beam scanning proton therapy

Physical and engineering sciences in medicine, 2020-12, Vol.43 (4), p.1241-1251

2020

Volltextzugriff (PDF)

Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study

The lancet oncology, 2015-04, Vol.16 (4), p.395-405

2015

Volltextzugriff (PDF)

Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer

Journal of clinical oncology, 2009-05, Vol.27 (13), p.2231-2237

2009

Volltextzugriff (PDF)

Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Gemcitabine/Cisplatin Alone or With Sorafenib for the First-Line Treatment of Advanced, Nonsquamous Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2012-09, Vol.30 (25), p.3084-3092

2012

Volltextzugriff (PDF)

Gemcitabine plus platinum-based chemotherapy for first-line treatment of hepatocholangiocarcinoma: an AGEO French multicentre retrospective study

British journal of cancer, 2018-02, Vol.118 (3), p.325-330

2018

Volltextzugriff (PDF)

Aflibercept and Docetaxel Versus Docetaxel Alone After Platinum Failure in Patients With Advanced or Metastatic Non–Small-Cell Lung Cancer: A Randomized, Controlled Phase III Trial

Journal of clinical oncology, 2012-10, Vol.30 (29), p.3640-3647

2012

Volltextzugriff (PDF)

“Emergency” multidisciplinary team meeting in cancer: a first feedback from a care team

Journal of translational medicine, 2023-10, Vol.21 (1), p.1-767, Article 767

2023

Volltextzugriff (PDF)

Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study

The lancet oncology, 2011-03, Vol.12 (3), p.256-262

2011

Volltextzugriff (PDF)

Sensitization of EGFR Wild-Type Non-Small Cell Lung Cancer Cells to EGFR-Tyrosine Kinase Inhibitor Erlotinib

Molecular cancer therapeutics, 2017-08, Vol.16 (8), p.1634-1644

2017

Volltextzugriff (PDF)

STK11/LKB1 Modulation of the Immune Response in Lung Cancer: From Biology to Therapeutic Impact

Cells (Basel, Switzerland), 2021-11, Vol.10 (11), p.3129

2021

Volltextzugriff (PDF)

Characteristics and clinical outcomes of sarcomatoid carcinoma of the lung

Clinical lung cancer, 2016-09, Vol.17 (5), p.391-397

2016

Volltextzugriff (PDF)

1 – 25 von 326

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(316)
Mit Volltextzugriff
(294)

Publikationsform

Artikel
(325)
Berichte
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(168)
Science & Technology
(168)
Oncology
(134)
Humans
(127)
Male
(80)
Female
(78)
Aged
(70)
Middle Aged
(67)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(59)
Life Sciences
(57)
Cancer
(56)
Adult
(54)
Chemotherapy
(49)
Tumors
(43)
Aged, 80 And Over
(40)
Lung Neoplasms - Drug Therapy
(38)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(31)
Treatment Outcome
(30)
Colorectal Cancer
(29)
Metastasis
(29)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Update on afatinib-based combination regimens for the treatment of EGFR mutation-positive non-small-cell lung cancer

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial

Two-Year Survival Comparing Web-Based Symptom Monitoring vs Routine Surveillance Following Treatment for Lung Cancer

Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations

Treatments for Non-Small-Cell Lung Cancer: The Multiple Options for Precision Medicine

Infiltrating and peripheral immune cell analysis in advanced gastric cancer according to the Lauren classification and its prognostic significance

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer

Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial

Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab

Investigating beam matching for multi-room pencil beam scanning proton therapy

Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study

Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer

Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Gemcitabine/Cisplatin Alone or With Sorafenib for the First-Line Treatment of Advanced, Nonsquamous Non–Small-Cell Lung Cancer

Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial

The inhibitory receptor CD94/NKG2A on CD8 + tumor-infiltrating lymphocytes in colorectal cancer: a promising new druggable immune checkpoint in the context of HLAE/β2m overexpression

Gemcitabine plus platinum-based chemotherapy for first-line treatment of hepatocholangiocarcinoma: an AGEO French multicentre retrospective study

Aflibercept and Docetaxel Versus Docetaxel Alone After Platinum Failure in Patients With Advanced or Metastatic Non–Small-Cell Lung Cancer: A Randomized, Controlled Phase III Trial

“Emergency” multidisciplinary team meeting in cancer: a first feedback from a care team

Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study

Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial

Sensitization of EGFR Wild-Type Non-Small Cell Lung Cancer Cells to EGFR-Tyrosine Kinase Inhibitor Erlotinib

STK11/LKB1 Modulation of the Immune Response in Lung Cancer: From Biology to Therapeutic Impact

Characteristics and clinical outcomes of sarcomatoid carcinoma of the lung

Suchergebnisse filtern